financetom
Business
financetom
/
Business
/
Novo Nordisk Unusual Options Activity For August 06
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Novo Nordisk Unusual Options Activity For August 06
Aug 6, 2024 8:47 AM

Deep-pocketed investors have adopted a bullish approach towards Novo Nordisk ( NVO ) , and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in NVO usually suggests something big is about to happen.

We gleaned this information from our observations today when Benzinga's options scanner highlighted 15 extraordinary options activities for Novo Nordisk ( NVO ). This level of activity is out of the ordinary.

The general mood among these heavyweight investors is divided, with 46% leaning bullish and 46% bearish. Among these notable options, 7 are puts, totaling $538,503, and 8 are calls, amounting to $580,397.

What's The Price Target?

Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $110.0 to $150.0 for Novo Nordisk ( NVO ) over the recent three months.

Insights into Volume & Open Interest

In today's trading context, the average open interest for options of Novo Nordisk ( NVO ) stands at 656.29, with a total volume reaching 1,904.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Novo Nordisk ( NVO ), situated within the strike price corridor from $110.0 to $150.0, throughout the last 30 days.

Novo Nordisk Option Volume And Open Interest Over Last 30 Days

Biggest Options Spotted:

Symbol PUT/CALL Trade Type Sentiment Exp. Date Ask Bid Price Strike Price Total Trade Price Open Interest Volume
NVO PUT SWEEP BEARISH 08/16/24 $11.5 $10.05 $10.05 $138.00 $214.9K 137 291
NVO CALL SWEEP BEARISH 03/21/25 $28.75 $28.6 $28.6 $110.00 $143.0K 159 51
NVO CALL SWEEP BEARISH 12/20/24 $5.35 $5.3 $5.3 $150.00 $106.0K 983 206
NVO CALL SWEEP BULLISH 03/21/25 $21.35 $21.25 $21.35 $120.00 $100.3K 97 50
NVO PUT SWEEP BULLISH 09/20/24 $9.95 $9.85 $9.95 $135.00 $78.6K 1.7K 87

About Novo Nordisk

With roughly one third of the global branded diabetes treatment market, Novo Nordisk ( NVO ) is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Following our analysis of the options activities associated with Novo Nordisk ( NVO ), we pivot to a closer look at the company's own performance.

Where Is Novo Nordisk Standing Right Now?

Currently trading with a volume of 2,201,233, the NVO's price is up by 3.24%, now at $130.08.

RSI readings suggest the stock is currently is currently neutral between overbought and oversold.

Anticipated earnings release is in 1 days.

What Analysts Are Saying About Novo Nordisk

1 market experts have recently issued ratings for this stock, with a consensus target price of $160.0.

In a cautious move, an analyst from Cantor Fitzgerald downgraded its rating to Overweight, setting a price target of $160.

Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Novo Nordisk ( NVO ) with Benzinga Pro for real-time alerts.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Delta Air Lines Q2 Earnings: EPS Miss, Revenue Beat, Underwhelming Q3 EPS Outlook And More
Delta Air Lines Q2 Earnings: EPS Miss, Revenue Beat, Underwhelming Q3 EPS Outlook And More
Jul 11, 2024
Delta Air Lines, Inc. ( DAL ) shares are trading lower by ~9% premarket on Thursday following the release of its second-quarter 2024 results. Delta reported second-quarter 2024 operating revenue growth of 7% year-over-year to $16.658 billion, beating the consensus of $15.452 billion. Adjusted operating revenue was $15.407 billion (+5.4% YoY). Adjusted average fuel price of $2.64 per gallon, up...
Top Premarket Gainers
Top Premarket Gainers
Jul 11, 2024
07:51 AM EDT, 07/11/2024 (MT Newswires) -- Volcon ( VLCN ) shares were up over 80% premarket Thursday following a 6.2% fall in the previous session. Blue Star Foods ( BSFC ) stock was 77% higher after Wednesday's 4.6% loss. Cyngn ( CYN ) shares were up 59% after the company said it added Alta Equipment Group to its dealer...
Royal Bank of Canada Names Deputy Chair, Changes Business Segments
Royal Bank of Canada Names Deputy Chair, Changes Business Segments
Jul 11, 2024
07:51 AM EDT, 07/11/2024 (MT Newswires) -- Royal Bank of Canada ( RY ) on Thursday named a new deputy chair and made changes to its business segments that will become effective on Sept. 1. Doug Guzman, currently serving as group head of RBC Wealth Management and Insurance, will assume the deputy chair role at RBC. Guzman will remain a...
Pfizer to Advance Development of Modified-Release Formulation of Danuglipron
Pfizer to Advance Development of Modified-Release Formulation of Danuglipron
Jul 11, 2024
07:53 AM EDT, 07/11/2024 (MT Newswires) -- Pfizer ( PFE ) said Thursday it will conduct dose optimization studies of danuglipron in the second half of the year after selecting a once-daily, modified-release formulation of the drug candidate, intended to maintain healthy blood sugar levels and address obesity. According to the company, the decision was based on results from an...
Copyright 2023-2026 - www.financetom.com All Rights Reserved